USA - NASDAQ:REVB - US76135L7055 - Common Stock
The current stock price of REVB is 1.54 USD. In the past month the price decreased by -39.37%. In the past year, price decreased by -96.2%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 21.01 | 393.01B | ||
AMGN | AMGEN INC | 13.09 | 153.65B | ||
GILD | GILEAD SCIENCES INC | 14.74 | 141.56B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 22.62 | 98.23B | ||
REGN | REGENERON PHARMACEUTICALS | 12.97 | 62.75B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.45B | ||
ARGX | ARGENX SE - ADR | 79.48 | 45.09B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.83 | 39.75B | ||
INSM | INSMED INC | N/A | 30.60B | ||
NTRA | NATERA INC | N/A | 24.86B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.13B | ||
BIIB | BIOGEN INC | 8.9 | 20.89B |
Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2020-10-08. The firm's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The firm has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection.
REVELATION BIOSCIENCES INC
4660 Lajolla Village Drive, Suite 100
San Diego CALIFORNIA US
Employees: 9
Phone: 16508003717
The current stock price of REVB is 1.54 USD. The price decreased by -1.28% in the last trading session.
The exchange symbol of REVELATION BIOSCIENCES INC is REVB and it is listed on the Nasdaq exchange.
REVB stock is listed on the Nasdaq exchange.
7 analysts have analysed REVB and the average price target is 21.68 USD. This implies a price increase of 1307.47% is expected in the next year compared to the current price of 1.54. Check the REVELATION BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
REVELATION BIOSCIENCES INC (REVB) has a market capitalization of 2.62M USD. This makes REVB a Nano Cap stock.
REVELATION BIOSCIENCES INC (REVB) currently has 9 employees.
REVELATION BIOSCIENCES INC (REVB) has a resistance level at 2.01. Check the full technical report for a detailed analysis of REVB support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
REVB does not pay a dividend.
REVELATION BIOSCIENCES INC (REVB) will report earnings on 2025-11-06, before the market open.
REVELATION BIOSCIENCES INC (REVB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-68.6).
The outstanding short interest for REVELATION BIOSCIENCES INC (REVB) is 13.68% of its float. Check the ownership tab for more information on the REVB short interest.
ChartMill assigns a fundamental rating of 2 / 10 to REVB. The financial health of REVB is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months REVB reported a non-GAAP Earnings per Share(EPS) of -68.6. The EPS increased by 88.94% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -215.84% | ||
ROE | -304.37% | ||
Debt/Equity | 0 |
7 analysts have analysed REVB and the average price target is 21.68 USD. This implies a price increase of 1307.47% is expected in the next year compared to the current price of 1.54.